Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.158NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.602NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.289NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.7.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDHNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.48NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EK.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.66NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GS.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.258.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.21.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.39NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EE.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
ES.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.19.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.479NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.437NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.4.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HU.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JC.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.625NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GY.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GW.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.40NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.367NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.3.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.385NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.45NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.244NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.17.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.7.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.10.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used